Michael Jirousek - Catabasis Pharmaceuticals Insider

Catabasis Pharmaceuticals Inc -- USA Stock  

USD 1.74  0.065  3.88%

Co-Founder and Member of Scientific Advisory Board

Dr. Michael Jirousek, Ph.D. is the CoFounder and Chief Scientific Officer of Catabasis Pharmaceuticals, Inc. He has more than twenty years of experience in pharmaceutical research and development. Prior to joining the Company, he was a Corporationrationrate Officer and Senior Vice President of research at Sirtris Pharmaceuticals, where he was Head of Research for the company. He joined Sirtris from Pfizer La Jolla, part of Pfizer Global Research and Development, where he was Senior Director and Head of the Metabolic Therapeutic Area. He founded the La Jolla group. Prior to joining Pfizer, he was the Department Head at Abbott Laboratories for three years. He spent eight years at Eli Lilly in Indianapolis and Hamburg, Germany, focusing on diabetic complications and PKC inhibitors
Age: 55  Founder Since 2008  Ph.D    
617-349-1971  http://www.catabasis.com
Jirousek holds a Ph.D. in chemistry from Case Western Reserve University and was a postdoctoral fellow at Harvard University and holds a Ph.D. in Chemistry from Case Western University and a B.S. in Chemistry from Kent State University.

Management Efficiency

The company has return on total asset (ROA) of (52.43) % which means that it has lost $52.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (116.7) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.3 M in liabilities with Debt to Equity (D/E) ratio of 21.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Catabasis Pharmaceuticals Inc has Current Ratio of 2.96 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 38 people.Catabasis Pharmaceuticals Inc (CATB) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 38 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Catabasis Pharmaceuticals Inc to your portfolio

Top Management

Catabasis Pharmaceuticals Leadership Team
Jean George, Director, MBA
Angelika Fretzen, President, MBA
Rick Modi, Executive, MBA
Joanne Donovan, Executive, Ph.D
Deirdre Cunnane, President
Michael Jirousek, Founder, Ph.D
Michael Kishbauch, Director, MBA
Edward Hibben, Executive, MBA
Ian Sanderson, CFO, MBA
Burt Adelman, Director, Ph.D
Deirdre JD, SVP
Kenneth Bate, Director, MBA
Jill Milne, CEO, Ph.D
Andrea Matthews, Executive
Nicholas Galakatos, Director, Ph.D
Ron Laufer, Director, MBA
Michael Ross, Chairman, Ph.D
Andrew Nichols, SVP, Ph.D
Ted Hibben, SVP, MBA

Stock Performance

Catabasis Pharmaceuticals Performance Indicators